ArticleJugan geon-gang gwa jilbyeong2025
[The Republic of Korea 2023-2024 Influenza and Respiratory Viruses Laboratory Surveillance Report].
Article in Jugan geon-gang gwa jilbyeong, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The study aim was to examine the detection patterns of respiratory virus circulation in the Republic of Korea from week 36 of 2023 to week 35 of 2024, with a focus on characterizing influenza viruses. The purpose of this study was to support the selection of vaccine strains and strengthen public health preparedness. Methods: Respiratory specimens were collected from 18,040 symptomatic individuals using a national sentinel surveillance network. Real-time reverse transcription polymerase chain reaction testing was performed to identify the causative respiratory pathogens. For influenza viruses, further analyses were performed to assess genetic similarity with the vaccine strains, antigenic characteristics, and antiviral resistance. Results: Influenza viruses were detected in 15.1% of specimens, with the following subtype distributions: A(H1N1)pdm09 (41.7%), A(H3N2) (29.3%), and B type (29.1%). The genetic analysis showed that the circulating strains belonged to phylogenetic groups similar to the current vaccine strains. Further, no mutations associated with resistance to antiviral drugs (Oseltamivir, Zanamivir, and Peramivir, Baloxavir) were identified. The antigenic analysis confirmed effective neutralizing activity against the vaccine strains. Among respiratory viruses, severe acute respiratory syndrome coronavirus 2 was the most frequently detected (15.1%), followed by rhinovirus (14.9%), adenovirus (9.9%), parainfluenza virus (5.6%), respiratory syncytial virus (5.0%), human metapneumovirus (4.2%), human coronavirus (3.8%), and bocavirus (3.2%). Conclusions: The continuous surveillance of influenza and respiratory virus trends is essential to inform vaccine strain selection and enhance public health response strategies. Our division will conduct continuous surveillance of the epidemiological trends of respiratory viruses, including influenza, and ensure the timely provision of data for public health interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.